Rohrberg et al. [17] reported that immunohistochemical expression of VEGF-A could be a biomarker for the efficacy of bevacizumab in upper gastrointestinal cancers, including metastatic gastric cancer (GC). Here, VEGFA is linked to gastric cancer.